The Readout Loud 338: Chinese biotechs, a WHO departure, and post-JPM thoughts
19 snips
Jan 23, 2025 Engaging discussions highlight the rise of Chinese biotechs in global drug development, emphasizing their growing influence and innovative potential. The hosts share a humorous anecdote from the JPM healthcare conference that underscores the camaraderie in the industry. Additionally, insights from an infectious disease reporter reveal the significant implications of the U.S. withdrawal from the WHO, focusing on its impact on public health priorities and international cooperation.
AI Snips
Chapters
Transcript
Episode notes
Unexpected Reunion
- Allison DeAngelis recounts a humorous encounter at JPM with former co-host Damien Garde.
- She apologized for interrupting him, only for him to reply, "I know who you are."
China's Biotech Boom
- China's role in drug development is rapidly expanding, impacting US biotech.
- A third of drugs bought by pharma in 2023 originated from China, up from zero four years prior.
China's Speed Advantage
- Chinese scientists possess a competitive edge in early-stage drug development.
- This speed allows them to advance programs faster than their US counterparts.